Episode Details
Back to Episodes
#074: S1P Modulators - Fingolimod (Gilenya), Ozanimod (Zeposia), Ponesimod (Ponvory), Siponimod (Mayzent) for active RRMS & SPMS
Description
Learn more about the S1P Modulators, known by the brand names Gilenya, Zeposia, Ponvory, Mayzent and their usage against active RRMS & SPMS.
You can find the complete text to read on my blog: https://ms-perspektive.com/074-s1p-modulators
Today it's all about the group of S1P modulators, which includes fingolimod (Gilenya), ozanimod (Zeposia), ponesimod (Ponvory) and siponimod (Mayzent). The first three, i.e. Gilenya, Zeposia and Ponvory, are used as a disease-modifying therapy for active multiple sclerosis. Fingolimod (Gilenya) is even approved for pediatric MS. Mayzent is approved for active SPMS if the patient is already experiencing a worsening of MS independent of relapses, but also has localized inflammatory activity.
S1P modulators are pronounced sphingosine 1-phosphate receptor modulators and prevent the leakage of lymphocytes from the lymph nodes. This also prevents them from entering the central nervous system (CNS). The S1P receptor subgroups determine the side effect profile.
Please remember that I can only provide an overview here. Your neurologist and your MS nurse should advise you in detail on the right therapy for you. This is because they know your general state of health and you should also talk about your goals, wishes, fears and preferences so that these can be taken into account.
"},"minimize_box":"yes","minimized_on":"tablet","hierarchical_view":"yes","min_height":{"unit":"px","size":"","sizes":[]},"min_height_tablet":{"unit":"px","size":"","sizes":[]},"min_height_mobile":{"unit":"px","size":"","sizes":[]}}" data-widget_type="table-of-contents.default"> Table of Contents- General Information
- How are S1P Modulators – Fingolimod (Gilenya), Ozanimod (Zeposia), Ponesimod (Ponvory), Siponimod (Mayzent) classified in immunotherapies?
- What are fingolimod (Gilenya), ozanimod (Zeposia), ponesimod (Ponvory), and siponimod (Mayzent) approved for?
- What is the situation for special patient groups?
- Who should avoid fingolimod (Gilenya), ozanimod (Zeposia), ponesimod (Ponvory), and siponimod (Mayzent)?
- How do fingolimod (Gilenya), ozanimod (Zeposia), ponesimod (Ponvory), and siponimod (Mayzent) work?
- How is it taken?
- How effective are fingolimod (Gilenya), ozanimod (Zeposia), ponesimod (Ponvory), and siponimod (Mayzent)?
- Risks and side effects of fingolimod (Gilenya), ozanimod (Zeposia), ponesimod (Ponvory), and siponimod (Mayzent)
- Vaccinations
- Sources
Listen Now
Love PodBriefly?
If you like Podbriefly.com, please consider donating to support the ongoing development.
Support Us